Skip to main content

Editors' Profile

Dr Franco M Buonaguro, Co-Editor-in-Chief

Dr. Franco M. Buonaguro obtained his Medical Doctor degree at the University of Naples, Italy, in 1977, where he also became Specialist in Endocrinology in 1982, Microbiology and Virology in 1992. After a postdoctoral fellowship at the Department of Cell Biology, Argonne National Laboratory, Argonne, IL, USA (1979-81), a WHO Fellowship and research associate position at the Tumor Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA (1983-86), he became an assistant member of the Experimental Oncology F – Viral Oncology at Natl Cancer Institute in Naples. He was promoted associate member in 1991, and became full member in 2001. Since 2008 Dr F.M. Buonaguro is Director of the Molecular Biology and Viral Oncogenesis Unit of the Experimental Oncology Department at the Natl Cancer Institute “Fond Pascale “ Napoli-Italy.

If you would like to contact Dr Buonaguro directly regarding a submission to the journal, please contact him on: fmbuonaguro@tim.it



Dr Sam M Mbulaiteye, Co-Editor-in-Chief

As a senior investigator in the Infections and Immunoepidemiology Branch (IIB), Dr. Mbulaiteye focuses his research on unraveling the role of infections, immunity, and genetic factors in the etiology of Burkitt lymphoma and Kaposi sarcoma. Both of these malignancies are endemic in Africa and their risk is substantially increased in the setting of HIV/AIDS.

Dr. Mbulaiteye received his primary medical degree from Makerere University, Kampala (1990). He earned advanced degrees in epidemiology and biostatistics (M.Phil.) from the University of Cambridge, U.K. (1994), and received specialization in internal medicine (M.Med.) from Makerere University (1996). He began his research career at the Uganda Cancer Institute (1994-1997) by leading the fieldwork on a large case-control study to measure the impact of HIV on cancer in children and adults. He transitioned to the Uganda Virus Research Institute where he tracked the population dynamics of HIV by measuring incidence and prevalence of HIV in a large rural general population in southwest Uganda in a study funded by the U.K. Medical Research Council. Dr. Mbulaiteye joined IIB as a research fellow in December 2000, and was awarded scientific tenure by the NIH and appointed senior investigator in 2013.

Please visit the following website to read further information on Dr Mbulaiteye's career and research interests:

https://dceg.cancer.gov/about/staff-directory/biographies/O-Z/mbulaiteye-sam

If you would like to contact Dr Mbulaiteye directly regarding a submission to the journal, please contact him on: mbulaits@mail.nih.gov.

Dr Maria Lina Tornesello, Co-Editor-in-Chief

Dr Maria Lina Tornesello is the head of the Progression Markers and Viruses laboratory, section of Molecular Biology and Viral Oncology, at the Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy. Dr Tornesello graduated summa cum laude in Biological Science in 1988 and achieved the specialty in Microbiology and Virology in 1994 from the University Federico II (Napoli, Italy). She has carried out post-doctoral research programs at the Istituto Nazionale Tumori Fondazione Pascale and then, at the Tumor Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.  In 1993, she became assistant member and in 2001 associate member of the Experimental Oncology at the Istituto Nazionale Tumori Fondazione Pascale.  The research activities of Dr Tornesello mainly focused on viral-related tumorigenesis with particular interest in the study of viral and host interaction in HPV and genital cancer, HHV8 and Kaposi sarcoma, and HCV /HBV and liver cancer. More recently her research activities have been extended to the study of genetic alterations and pathways deregulation in the pathogenesis of viruses-driven tumors.

If you would like to contact Dr Tornesello directly regarding a submission to the journal, please contact her on: m.tornesello@istitutotumori.na.it

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.1
    5-year Journal Impact Factor: 3.3
    Source Normalized Impact per Paper (SNIP): 0.810
    SCImago Journal Rank (SJR): 0.424

    Speed 2023
    Submission to first editorial decision (median days): 12
    Submission to acceptance (median days): 112

    Usage 2023
    Downloads: 687,750
    Altmetric mentions: 813

What is trending?

Altmetric




               Click here to see which articles published in Infectious Agents and Cancer have been shared the most in the past three months.